|
|
Post by mnholdem on Mar 17, 2020 14:07:03 GMT -5
A collaboration with Immix makes no sense, although they do have a "nano-particle delivery vehicle" being used ( clinicaltrials.gov/ct2/show/NCT03382340 ) it's a phase 2 for cancer treatment. This PR makes me wonder if our CEO is setting himself up for a new job...  |
|
|
|
Post by liane on Mar 17, 2020 14:38:30 GMT -5
Most people use a glidescope now. liane is that what you use or do you prefer the old fashion way? I learned the old fashioned way - with a laryngoscope - and dare I say, in the back of a moving ambulance when I was a paramedic. Gave me nerves of steel during my internship year of training. Most interns would not have the skill or confidence to do the procedure. I once got called to the floor in the middle of the night for a patient in respiratory arrest. The resident physician (next up in the chain of command) did not show up until just as I was about to pass the tube. He was trying to tell me not to get nervous, take my time, etc... I just had to tune him out, but I was successful. But now, it's been almost 20 years since I've done an intubation - so I don't know what the latest greatest is. |
|
|
|
Post by MnkdWASmyRtrmntPlan on Mar 17, 2020 15:18:38 GMT -5
A collaboration with Immix makes no sense, although they do have a "nano-particle delivery vehicle" being used ( clinicaltrials.gov/ct2/show/NCT03382340 ) it's a phase 2 for cancer treatment. This PR makes me wonder if our CEO is setting himself up for a new job... God, I hope so. Wouldn't that be great! A hell of a lot faster and easier (and probably less expensive) than firing him. |
|
|
|
Post by jlaw277 on Mar 17, 2020 15:20:55 GMT -5
A collaboration with Immix makes no sense, although they do have a "nano-particle delivery vehicle" being used ( clinicaltrials.gov/ct2/show/NCT03382340 ) it's a phase 2 for cancer treatment. This PR makes me wonder if our CEO is setting himself up for a new job... This may offer something of an explanation: www.nytimes.com/2020/03/17/science/coronavirus-treatment.html"The researchers are looking for drugs that shield proteins in our own cells that the coronavirus depends on to thrive and reproduce. Many of the candidate drugs are already approved to treat diseases, such as cancer, that would seem to have nothing to do with Covid-19, the illness caused by the coronavirus." & "The flulike symptoms observed in infected people are the result of the coronavirus attacking cells in the respiratory tract. The new map shows that the virus’s proteins travel throughout the human cell, engaging even with proteins that do not seem to have anything to do with making new viruses." |
|
|
|
Post by mango on Mar 17, 2020 16:51:32 GMT -5
It’s unknown what percentage of people with COVID-19, the disease caused by the new coronavirus, will develop ARDS. A Chinese report published last month on hospitalized patients found that 3.4% had ARDS. At a media briefing Monday from the ARDS Foundation, Michael Matthay, a critical-care medicine doctor at University of California San Francisco, said he estimates that 1% to 3% of COVID-19 patients will get ARDS. www.inquirer.com/health/coronavirus/coronavirus-ards-acute-respiratory-distress-syndrome-pneumonia-penn-rutgers-20200317.htmlARDS is a rare lung condition and is often life threatening. People commonly die from ARDS. There is no FDA approved treatment for ARDS. This was a brilliant move and coincides with our new focus. Maybe, just maybe, we can make life more humann for people with ARDS. How great would that be? |
|
|
|
Post by rfogel on Mar 17, 2020 16:59:42 GMT -5
It’s unknown what percentage of people with COVID-19, the disease caused by the new coronavirus, will develop ARDS. A Chinese report published last month on hospitalized patients found that 3.4% had ARDS. At a media briefing Monday from the ARDS Foundation, Michael Matthay, a critical-care medicine doctor at University of California San Francisco, said he estimates that 1% to 3% of COVID-19 patients will get ARDS. www.inquirer.com/health/coronavirus/coronavirus-ards-acute-respiratory-distress-syndrome-pneumonia-penn-rutgers-20200317.htmlARDS is a rare lung condition and is often life threatening. People commonly die from ARDS. There is no FDA approved treatment for ARDS. This was a brilliant move and coincides with our new focus. Maybe, just maybe, we can make life more humann for people with ARDS. How great would that be? Has any country actually documented the percentage of diagnosed cases that progressed to ARDS? |
|
|
|
Post by mango on Mar 17, 2020 17:02:40 GMT -5
It’s unknown what percentage of people with COVID-19, the disease caused by the new coronavirus, will develop ARDS. A Chinese report published last month on hospitalized patients found that 3.4% had ARDS. At a media briefing Monday from the ARDS Foundation, Michael Matthay, a critical-care medicine doctor at University of California San Francisco, said he estimates that 1% to 3% of COVID-19 patients will get ARDS. www.inquirer.com/health/coronavirus/coronavirus-ards-acute-respiratory-distress-syndrome-pneumonia-penn-rutgers-20200317.htmlARDS is a rare lung condition and is often life threatening. People commonly die from ARDS. There is no FDA approved treatment for ARDS. This was a brilliant move and coincides with our new focus. Maybe, just maybe, we can make life more humann for people with ARDS. How great would that be? Has any country actually documented the percentage of diagnosed cases that progressed to ARDS? The indication will be for ARDS. ARDS just happens to be a rare complication associated with COVID-19. And, to answer your question, well, you'll just have to look and see. |
|
|
|
Post by barnstormer on Mar 17, 2020 17:15:38 GMT -5
Well if nothing else Mike has found a way to change the narrative away from his current failings of Afrezza to something else. Another spec play with no cash. It's like RLS 2.0. I have often wondered why if TS is so incredible (and I think it is) why hasn't management pursued more drug candidates where TS delivers something specifically beneficial for lungs ailments with a built in cough suppressant. What MNKD needs is a partner with cash, a sales force and a good drug. This euphoria will be short lived unless there is cash to get it to market.
|
|
|
|
Post by golfeveryday on Mar 17, 2020 17:21:12 GMT -5
It’s unknown what percentage of people with COVID-19, the disease caused by the new coronavirus, will develop ARDS. A Chinese report published last month on hospitalized patients found that 3.4% had ARDS. At a media briefing Monday from the ARDS Foundation, Michael Matthay, a critical-care medicine doctor at University of California San Francisco, said he estimates that 1% to 3% of COVID-19 patients will get ARDS. www.inquirer.com/health/coronavirus/coronavirus-ards-acute-respiratory-distress-syndrome-pneumonia-penn-rutgers-20200317.htmlARDS is a rare lung condition and is often life threatening. People commonly die from ARDS. There is no FDA approved treatment for ARDS. This was a brilliant move and coincides with our new focus. Maybe, just maybe, we can make life more humann for people with ARDS. How great would that be? A small percentage with Covid 19 may have ARDS but he could get it fast tracked because of Covid 19 and then use it for a greater population all while getting a ton of eyes and interest on this stock. |
|
|
|
Post by mango on Mar 17, 2020 17:31:24 GMT -5
It’s unknown what percentage of people with COVID-19, the disease caused by the new coronavirus, will develop ARDS. A Chinese report published last month on hospitalized patients found that 3.4% had ARDS. At a media briefing Monday from the ARDS Foundation, Michael Matthay, a critical-care medicine doctor at University of California San Francisco, said he estimates that 1% to 3% of COVID-19 patients will get ARDS. www.inquirer.com/health/coronavirus/coronavirus-ards-acute-respiratory-distress-syndrome-pneumonia-penn-rutgers-20200317.htmlARDS is a rare lung condition and is often life threatening. People commonly die from ARDS. There is no FDA approved treatment for ARDS. This was a brilliant move and coincides with our new focus. Maybe, just maybe, we can make life more humann for people with ARDS. How great would that be? A small percentage with Covid 19 may have ARDS but he could get it fast tracked because of Covid 19 and then use it for a greater population all while getting a ton of eyes and interest on this stock. It can be fast tracked regardless of COVID-19 because it is ARDS. The COVID-19 association may, and probably will, help in many ways as well. Eyes and interests. It will be fast-tracked plus given orphan status. More eyes and interests. |
|
|
|
Post by mango on Mar 17, 2020 17:39:10 GMT -5
What does it mean to have Orphan Drug Status?
The purpose of the designation was to create financial incentives for companies to develop new drugs and biologics for rare diseases. These incentives include a partial tax credit for clinical trial expenditures, waived user fees, and eligibility for 7 years of marketing exclusivity.
|
|
|
|
Post by peppy on Mar 17, 2020 17:54:27 GMT -5
It’s unknown what percentage of people with COVID-19, the disease caused by the new coronavirus, will develop ARDS. A Chinese report published last month on hospitalized patients found that 3.4% had ARDS. At a media briefing Monday from the ARDS Foundation, Michael Matthay, a critical-care medicine doctor at University of California San Francisco, said he estimates that 1% to 3% of COVID-19 patients will get ARDS. www.inquirer.com/health/coronavirus/coronavirus-ards-acute-respiratory-distress-syndrome-pneumonia-penn-rutgers-20200317.htmlARDS is a rare lung condition and is often life threatening. People commonly die from ARDS. There is no FDA approved treatment for ARDS. This was a brilliant move and coincides with our new focus. Maybe, just maybe, we can make life more humann for people with ARDS. How great would that be? Has any country actually documented the percentage of diagnosed cases that progressed to ARDS? acute respiratory distress syndrome also exists with out COVID-19 Plenty of respiratory aliments. |
|
|
|
Post by mango on Mar 17, 2020 17:57:46 GMT -5
This patent. I see at least one potential ARDS treatment.
8. The dry powder inhaler of claim 6, wherein the active ingredient is selected from the group consisting of insulin, glucagon-like peptide 1, oxyntomodulin, peptide YY, exendin, heparin, calcitonin, felbamate, sumatriptan, parathyroid hormone, growth hormone, erythropoietin, zidovudine, didanosine, granulocyte macrophage colony stimulating factor, lamotrigine, chorionic gonadotropin releasing factor, luteinizing releasing hormone, beta-galactosidase, exendin, vasoactive intestinal peptide, argatroban, anti-SSX-241-49 (synovial sarcoma, X breakpoint 2), anti-NY-ESO-1 (esophageal tumor associated antigen), anti-PRAME (preferentially expressed antigen of melanoma), anti-PSMA (prostate-specific membrane antigen), anti-Melan-A (melanoma tumor associated antigen), anti-tyrosinase (melanoma tumor associated antigen), and a combination thereof.
• Could also be a stem cell. Some kind of regenerative medicine. But, the Vasoactive Intestinal Peptide is one potential.
|
|
|
|
Post by ilovekauai on Mar 17, 2020 18:18:33 GMT -5
Well with the 8000 point drop, I have been staying away, convinced we'd be under a buck for the foreseeable future and concerned over that fun issue. So, pleasantly surprised this afternoon when I finally did take a peek and saw the nice close. I have no idea after reviewing these 4 pages of posts if this news is noteworthy or just a passing fancy, but guess we''lll know soon enough. Tomorrow is another day for Mannkind in Wonderland. Cheers.
|
|
|
|
Post by Clement on Mar 17, 2020 18:21:00 GMT -5
1% of 100 million cases of Covid-19 in the US is 1 million patients with ARDS. Not insignificant.
|
|
